Suggested remit: To appraise the clinical and cost effectiveness of daratumumab within its marketing authorisation in combination for newly diagnosed systemic amyloid light-chain amyloidosis.
Status Proposed
Process STA 2018
ID number 3748

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
14 September 2020 (10:00) Scoping workshop
15 July 2020 - 12 August 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance